Medical guidelines often allow for patients with these obesity-related health problems to qualify for treatments, such as metabolic wellness programs or advanced therapies, at a lower BMI than those without such conditions
The SELECT trial, published in 2024, showed that semaglutide reduced major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) by 20% in individuals with obesity, even independent of weight loss magnitude. Why
In this approach, a recombinant protein of interest is commonly fused to a variety of tags (including the His6-tag, maltose-binding protein, and GST) to detect, purify, and pull down the interacting partners of a protein of interest
Semaglutide has an outstanding weight-loss effect and is evaluated as the first time that humans have achieved weight-loss effects that could only be achieved by surgery before using drugs